TABLE 1.
Baseline participant demographics and clinical characteristics
| Characteristic | n (%) |
|---|---|
| Age | |
| 60–64 years | 4 (26.7%) |
| ≥65 | 11 (73.3%) |
| Median [IQR]: 67 [64–73] | |
| Gender | |
| Male | 10 (66.7%) |
| Race | |
| White | 11 (73.3%) |
| Black | 1 (6.7%) |
| Asian | 3 (20.0%) |
| MoCA score | |
| 0–25 | 8 (53.3%) |
| ≥26 | 7 (46.7%) |
| Median [IQR]: 25 [21–27] | |
| HY stage 1 | |
| Stage 2 | 8 (53.3%) |
| Stage 3 | 7 (46.7%) |
| MDS‐UPDRS part III score 1 | |
| 1–19 | 0 (0%) |
| 20–38 | 6 (40%) |
| ≥39 | 9 (60%) |
| Median [IQR]: 41 [31–50] | |
| Disease duration 2 | |
| 0–4 years | 2 (13.3%) |
| ≥5 | 13 (86.7%) |
| Median [IQR]: 8 [5–8] | |
| LEDD | |
| 0–100 mg/day | 1 (6.7%) |
| 101–399 | 2 (13.3%) |
| 400–999 | 10 (66.7%) |
| ≥1000 | 2 (13.3%) |
| Median [IQR]: 550 [400–850] | |
| History of a fall within the last year | |
| Yes | 12 (80%) |
| No | 3 (20%) |
| History of recurrent falls within the last year | |
| Yes | 11(73.3%) |
| No | 4 (26.7%) |
| Subjective history of freezing‐of‐gait 3 | |
| Yes | 13 (86.7%) |
| No | 2 (13.3%) |
| History of falls during 10‐week study period | |
| Yes | 10 (66.7%) |
| No | 5 (33.3%) |
1Assessed in the OFF‐dopaminergic medication state.
2From initial motor symptoms.
3
Based on interview and response to the New Freezing of Gait Questionnaire.
Abbreviations: IQR, Interquartile range; MoCA, Montreal Cognitive Assessment; HY, Hoehn and Yahr Scale; MDS‐UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale; LEDD, total levodopa‐equivalent daily dose.